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Sry-related high-mobility box 2 (SOX2) is a critical tran-
scription factor that plays an important role in various phases
of embryonic development and maintenance of undifferen-
tiated embryonic stem cells (ESCs) (Feng and Wen, 2015).
SOX2, as one of the Yamanaka factors, is involved in the
conversion of mouse embryonic fibroblast cells (MEFs) into
induced pluripotent stem cells (iPSCs) (Takahashi and
Yamanaka, 2006). Recently, SOX2 amplification, usually
couples with aberrantly increased expression, were found in
various human cancers, including breast, lung, esophagus,
colon, prostate, ovarian among the others (Novak et al.,
2019). SOX2 overexpression promotes cancer progression
by accelerating cell proliferation, colony formation, migration,
invasion, and sphere formation. Furthermore, SOX2 is cau-
sally related to the development of the resistance of cancer
cells to chemotherapy, radiotherapy and targeted therapy in
different types of human cancers, likely due to its ability to
maintain the stemness of cancer stem cells (CSCs), which
are defined as a subpopulation within tumor cells being
equipped with stem cell-like properties that survives the
treatment and initiates tumor progression (Novak et al.,
2019). Thus, SOX2 has been validated as an attractive anti-
cancer target (Huser et al., 2018).
Given its biological significance, SOX2 levels are pre-
cisely controlled by a complicated network of transcriptional,
post-transcriptional, and post-translational regulators. At the
transcriptional level, the two isoforms of E2f transcription
factor 3 (E2f3), E2f3a and E2f3b, regulate SOX2 expression
in a reciprocal way (Wuebben and Rizzino, 2017). The
cyclin-dependent kinase inhibitor p21 directly binds to the
SOX2 enhancer and negatively regulates SOX2 transcrip-
tion (Wuebben and Rizzino, 2017), whereas transforming
growth factor-β (TGFβ) or sirtuin 1 (SIRT1) induces SOX2
via SOX4 (Wuebben and Rizzino, 2017), or via chromatin-
based epigenetic modification (Liu et al., 2016), respectively.
More recently, a homeobox-containing transcription factor,
muscle segment homeobox-2 (MSX2) was shown to desta-
bilize the pluripotency circuitry by direct binding to
the SOX2 promoter to repress SOX2 transcription (Wu et al.,
2015). At the post-transcriptional level, SOX2 is subjected to
regulation by several microRNAs and long non-coding RNAs
in cancer cells (Wuebben and Rizzino, 2017). Finally, at the
post-translational level, SOX2 protein is modulated by
phosphorylation, sumoylation, methylation, acetylation and
ubiquitylation. Phosphorylation of SOX2 at S249, S250 and
S251 residues affects its stability (Wuebben and Rizzino,
2017), whereas sumoylation of SOX2 impairs its DNA-
binding property and thus inhibiting its transcription activity
(Wuebben and Rizzino, 2017). Notably, SOX2 is subjected
to ubiquitylation by ubiquitin-conjugating enzyme UBE2S
and CUL4ADET1-COP1 E3 ligase, respectively (Cui et al.,
2018; Wuebben and Rizzino, 2017). The methylation of
SOX2 is required for ubiquitylation and proteolysis mediated
by HECT domain-containing WWP2 E3 ligase (Wuebben
and Rizzino, 2017), and the CRL4DCAF5 ubiquitin ligase
complex (Zhang et al., 2019).
Although SOX2 is highly relevant to cancer initiation,
progression and development of drug resistance, directly
targeting SOX2 has been proved to be difficult, since SOX2
is an “undrugable” transcription factor. The multiple preclin-
ical studies have shown that SOX2 knockdown mediated by
siRNAs, shRNAs or miRNAs dramatically suppresses pro-
liferation and invasion of cancer cells in both in vitro cell
culture and in vivo xenograft tumor models (Huser et al.,
2018). These studies validate SOX2 as a promising target,
but offer little therapeutic value due to huge challenge in
efficacy and delivery. On the other hand, zinc-finger (ZF)-
based artificial transcription factors (ATFs), which bind











genomic sequences with potentially single locus specificity,
provide an opportunity to modify, edit, and sculpt the epi-
genetic and transcriptional state of endogenous promoters.
Indeed, ATFs that bind to the proximal SOX2 promoters
were shown to cause ∼95% reduction of endoge-
nous SOX2 mRNA and protein in breast cancer cells upon
retrovirus-based delivery (Huser et al., 2018). Significantly,
these ATFs efficiently inhibited tumor growth in a xenograft
model of breast cancer with the inhibitory effect maintained
for a long term (Huser et al., 2018). Again, the challenge in
the in vivo delivery of ATFs to solid tumor tissues constrains
the clinical applications.
Given these limitations, targeting signal molecules
upstream or downstream of SOX2 become attractive alter-
native approaches. Several small molecules have been
reported to down-regulate SOX2 expression. For examples,
a small molecular inhibitor of LSD1 (CBB1007) significantly
reduced SOX2 expression and suppressed growth of tumor
cells. Mechanistically, LSD1 inactivation enhanced repres-
sive H3K9 methylations on the Sox2 gene (Zhang et al.,
2013). This newly developed inhibitor, however, is still in a
preclinical stage and its potential clinical application is
unknown. Furthermore, the cationic triphenylmethane phar-
macophore gentian violet (GV) has been recently reported to
suppress survival and self-renewal of melanoma cells
through the inhibition of SOX2. Mechanistic study revealed
that GV strongly decreased signal transducer and activator
of transcription 3 (STAT3) phosphorylation at Tyr705 through
an epidermal growth factor receptor (EGFR)-dependent
manner, leading to reduced STAT3 nuclear translocation for
SOX2 promoter binding (Pietrobono et al., 2016). Given that
GV is initially used as an antimycotic and antibacterial agent,
its clinical application as an anticancer agent awaits further
investigation. Finally, EGFR inhibitors, Gefitinib and Erlotinib,
and Src inhibitor, Dasatinib, are all shown to reduce the
levels of SOX2 by blocking the EGFR/SRC/AKT signaling,
eventually suppressing the self-renewal properties of cancer
stem cells in non-small cell lung cancer (Singh et al., 2012).
Although various EGFR inhibitors are currently under clinical
use, it is unknown how much its anti-cancer activity is
attributable to SOX2 depletion.
Most recently, we found that neddylation inhibitor,
MLN4924, also known as Pevonedistat, a small molecule
currently in phase II clinical trials for anticancer application
(Zhou et al., 2018), effectively depletes SOX2 via targeting
the FBXW2-MSX2 axis (Yin et al., 2019). Neddylation is a
reversible process catalyzed in a three-step enzymatic
cascade by E1 NEDD8-activating enzyme (NAE), E2
NEDD8-conjugating enzymes (UBE2M/UBC12 or UBE2F),
and NEDD8 E3 ligases, leading to attachment of ubiquitin-
like NEDD8 to a lysine residue of targeted substrates (Zhao
et al., 2014). The physiological substrates of neddylation are
cullin family members, which are the scaffold subunit of
cullin-RING ligase (CRL), whose activity requires cullin
neddylation (Zhao et al., 2014). The founding member of
CRL is SCF (SKP1, Cullin-1, and F-box protein) E3 ubiquitin
ligase, which promotes ubiquitylation and degradation of
many short-lived signal molecules (Nakayama and
Nakayama, 2006). In our effort to elucidate potential tran-
scription regulation of MLN4924, we performed an RNAseq
analysis and found that SOX2 transcription is significantly
down-regulated by MLN4924 in time and dose dependent
manner. Mechanistic study revealed that MLN4924 caused
accumulation of MSX2, a transcription repressor known to
suppress SOX2 expression (Wu et al., 2015). Further
investigation identified MSX2 as a substrate of SCFFBXW2 E3
ligase for targeted ubiquitylation and degradation. By
inhibiting Cullin-1 neddylation, MLN4924 inactivates
SCFFBXW2 E3 ligase to cause accumulation of MSX2, lead-
ing to SOX2 downregulation. Biologically, FBXW2 promotes
tumor sphere formation by upreglating SOX2 via inducing
MSX2 degradation, while MLN4924 sensitizes breast cancer
cells to tamoxifen by depleting SOX2 via targeting the
FBXW2-MSX2 axis (Yin et al., 2019). Our study, therefore,
provides a novel mechanism by which MLN4924 regulates
cancer stem cell property and overcomes tamoxifen resis-
tance with potential therapeutic application in targeting













Figure 1. A negative cascade of the FBXW2–MSX2–
SOX2 axis is targeted by MLN4924. SOX2 (cicada) is a
transcriptional downstream target of MSX2 (mantis). Upon
binding to SOX2 gene promoter, MSX2 negatively controls
SOX2 transcription. MSX2, on the other hand, is a
substrate of FBXW2 (oriole) E3 ligase. Upon hypoxia,
FBXW2 binds to MSX2 and targets it for ubiquitylation and
subsequent degradation. By inactivating FBXW2,
MLN4924 (man with a slingshot) causes MSX2 accumu-
lation to transcriptionally repress SOX2.
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Our study can extend an old Chinese saying: “The mantis
stalks the cicada, unaware of the oriole lurking behind itself
(螳螂捕蝉黄雀在后)” by adding “and oriole is unware of a
man with slingshot behind itself (Fig. 1). Here we designate
the MLN4924 to be a man with slingshot, who ultimately
targets the cicada (SOX2) via oriole (FBXW2) and mantis
(MSX2), to regulate stem cell property and sensitize breast
cancer cells to tamoxifen.
ACKNOWLEDGEMENTS
This work is supported by the NCI grant CA 156744 (YS).
COMPLIANCE WITH ETHICS GUIDELINES
Shizhen Zhang and Yi Sun declare that they have no conflict of
interest. This article does not contain any studies with human or
animal subjects performed by the any of the authors.
OPEN ACCESS
This article is distributed under the terms of the Creative Commons
Attribution 4.0 International License (http://creativecommons.org/
licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to
the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made.
REFERENCES
Cui CP, Zhang Y, Wang C, Yuan F, Li H, Yao Y, Chen Y, Li C, Wei W,
Liu CH et al (2018) Dynamic ubiquitylation of Sox2 regulates
proteostasis and governs neural progenitor cell differentiation.
Nat Commun 9:4648
Feng R, Wen J (2015) Overview of the roles of Sox2 in stem cell and
development. Biol Chem 396:883–891
Huser L, Novak D, Umansky V, Altevogt P, Utikal J (2018) Targeting
SOX2 in anticancer therapy. Expert Opin Ther Targets 22:983–
991
Liu L, Liu C, Zhang Q, Shen J, Zhang H, Shan J, Duan G, Guo D,
Chen X, Cheng J et al (2016) SIRT1-mediated transcriptional
regulation of SOX2 is important for self-renewal of liver cancer
stem cells. Hepatology 64:814–827
Nakayama KI, Nakayama K (2006) Ubiquitin ligases: cell-cycle
control and cancer. Nat Rev Cancer 6:369–381
Novak D, Huser L, Elton JJ, Umansky V, Altevogt P, Utikal J (2019)
SOX2 in development and cancer biology. Semin Cancer Biol.
https://doi.org/10.1016/j.semcancer.2019.08.007
Pietrobono S, Morandi A, Gagliardi S, Gerlini G, Borgognoni L,
Chiarugi P, Arbiser JL, Stecca B (2016) Down-regulation of SOX2
underlies the inhibitory effects of the triphenylmethane gentian
violet on melanoma cell self-renewal and survival. J Investig
Dermatol 136:2059–2069
Singh S, Trevino J, Bora-Singhal N, Coppola D, Haura E, Altiok S,
Chellappan SP (2012) EGFR/Src/Akt signaling modulates Sox2
expression and self-renewal of stem-like side-population cells in
non-small cell lung cancer. Mol Cancer 11:73
Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells
from mouse embryonic and adult fibroblast cultures by defined
factors. Cell 126:663–676
Wu Q, Zhang L, Su P, Lei X, Liu X, Wang H, Lu L, Bai Y, Xiong T, Li D
et al (2015) MSX2 mediates entry of human pluripotent stem cells
into mesendoderm by simultaneously suppressing SOX2 and
activating NODAL signaling. Cell Res 25:1314–1332
Wuebben EL, Rizzino A (2017) The dark side of SOX2: cancer—a
comprehensive overview. Oncotarget 8:44917–44943
Yin Y, Xie CM, Li H, Tan M, Chen G, Schiff R, Xiong X, Sun Y (2019)
The FBXW2-MSX2-SOX2 axis regulates stem cell property and
drug resistance of cancer cells. Proc Natl Acad Sci USA
116:20528–20538
Zhang C, Leng F, Saxena L, Hoang N, Yu J, Alejo S, Lee L, Qi D, Lu
F, Sun H et al (2019) Proteolysis of methylated SOX2 protein is
regulated by L3MBTL3 and CRL4(DCAF5) ubiquitin ligase. J Biol
Chem 294:476–489
Zhang X, Lu F, Wang J, Yin F, Xu Z, Qi D, Wu X, Cao Y, Liang W, Liu
Y et al (2013) Pluripotent stem cell protein Sox2 confers
sensitivity to LSD1 inhibition in cancer cells. Cell Rep 5:445–457
Zhao Y, Morgan MA, Sun Y (2014) Targeting neddylation pathways
to inactivate Cullin-RING ligases for anti-cancer therapy. Antioxid
Redox Signal 21:2383–2400
Zhou L, Zhang W, Sun Y, Jia L (2018) Protein neddylation and its
alterations in human cancers for targeted therapy. Cell Signal
44:92–102









MLN4924 depletion of oncogenic SOX2 COMMENTARY
